Gb002, Inc.
Clinical trials sponsored by Gb002, Inc., explained in plain language.
-
New inhaled drug shows promise for Long-Term control of rare lung disease
Disease control OngoingThis study looks at the long-term safety of an inhaled medication called seralutinib for people with pulmonary arterial hypertension (PAH), a serious condition where high blood pressure damages the arteries in the lungs. About 316 participants who finished a previous seralutinib …
Phase: PHASE3 • Sponsor: GB002, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New inhaled drug aims to help patients with lung scarring and high blood pressure
Disease control TerminatedThis phase 3 trial tests an inhaled drug called seralutinib for people with pulmonary hypertension (high blood pressure in the lungs) caused by interstitial lung disease (lung scarring). About 480 adults will receive either seralutinib or a placebo for 24 weeks, followed by a lon…
Phase: PHASE3 • Sponsor: GB002, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC